Strides Arcolab agrees to receive $150 million as final settlement from Mylan

25 Sep 2014 Evaluate

Strides Arcolab has agreed to receive an amount of $150 million from Mylan Inc., USA as the full and final settlement against the Contingent Holdback of upto $250 million.

Earlier in December 2013, Strides Arcolab completed the sale of its injectables business, Agila Specialties, to Mylan for $1.75 billion, but $250 million of that had been held back by Mylan until certain regulatory conditions related to an injectables facility in India are satisfied.

Strides Arcolab is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.

 

Strides Pharma Scien Share Price

868.60 -6.75 (-0.77%)
16-May-2024 14:00 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1513.35
Dr. Reddys Lab 5730.35
Cipla 1408.80
Zydus Lifesciences 1007.00
Lupin 1670.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.